Vanda Pharmaceuticals | VNDA - Current Liabilities

Stock Price
7.44
Daily Change
0.02 0.27%
Monthly
0.40%
Yearly
56.63%
Q1 Forecast
4.24

Vanda Pharmaceuticals reported $117.87M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Akebia Therapeutics USD 133.38M 14.66M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Anika Therapeutics USD 19.09M 3.01M Sep/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Halozyme Therapeutics USD 837.23M 702.95M Sep/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Insmed USD 417.21M 105.53M Sep/2025
J&J USD 54.13B 3.26B Dec/2025
Lexicon Pharmaceuticals USD 34.84M 75.86M Jun/2025
Ligand Pharmaceuticals USD 30.54M 34.2M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.67M 143K Sep/2025
Moderna USD 1.68B 109M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vanda Pharmaceuticals USD 117.87M 3.62M Sep/2025
Veracyte USD 72.15M 4.28M Sep/2025